目的：观察布地奈德联合匹多莫德干预毛细支气管炎预防哮喘的临床效果。方法将93例呼吸道合胞病毒感染毛细支气管炎患儿随机分为观察组（47例）和对照组（46例），两组均予抗病毒及对症处理，对照组加匹多莫德口服2月，观察组在对照组基础上加布地奈德经储雾罐吸入，观察比较治疗后3个月患者T细胞亚群变化及2年内哮喘的发生率。结果3个月后观察组较对照组免疫功能显著提高（P＜0．01），2年内哮喘的发生率显著降低（χ2＝5．23，P＜0．05）。结论布地奈德联合匹多莫德干预毛细支气管炎预防哮喘效果显著。%Objective To understand the effect of the medicine of curing bronchiolitis with a combination of Budesonide and Pidotimod in preventing asthma.Method 93 children with respiratory syncytial virus infection bronchiolitis were chosen as the subjects for study and randomly divided into an experimental group (n=47) and a control group (n=46). Both groups were provided with anti-virus and symptomatic treatment.The control group took Pidotimod 0.4/time orally for 2 months.In addition to anti-virus and symptomatic treatment, the experimental group inhaled budesonide by spacer, 100 ug/time, 1 to 2 times per day, for two months.T-cell subsets and the incidence of asthma in the two years were observed and compared.Findings 3 months after treatment, the immune function in the experimental group was found to improve than in the control group ( P <0.01).Two years after treatment, the incidence of asthma was found to decrease significantly in the experimental group (P<0.05).The difference was significant.Conclusion The medicine of curing bronchiolitis with a combination of Budesonide and pidotimod first for preventing asthma has been proved to be effective.
展开▼
